OptimizeRx (OPRX) EBIT Margin (2010 - 2026)

OptimizeRx (OPRX) posted EBIT Margin of 2.0% for Q1 2026, down 92.49% sequentially from 26.58% in Q4 2025, and up 1158.0% YoY from 0.16% in Q1 2025.

OptimizeRx (OPRX) EBIT Margin (2010 - 2026) Analysis & Trends

OptimizeRx has reported EBIT Margin for 17 years, with the latest figure at 2.0% in Q1 2026.

Quarterly EBIT Margin rose 1158.0% year-over-year to 2.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.23% (up 2465.0% YoY) and the FY2025 annual result came in at 10.69%, up 2556.0% from the prior year.
EBIT Margin declined to 2.0% in Q1 2026 per OPRX's latest filing, from 26.58% in the prior quarter.
Over five years, EBIT Margin peaked at 26.58% in Q4 2025 and troughed at 54.32% in Q1 2023.
A 5-year average of 15.93% and a median of 21.76% in 2023 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2023 and 2024: EBIT Margin plunged 3404 bps in 2023, then soared 4968 bps in 2024.
Over 5 years, EBIT Margin stood at 4.4% in 2022, then slumped by 774 bps to 38.43% in 2023, then soared by 129 bps to 11.25% in 2024, then soared by 136 bps to 26.58% in 2025, then tumbled by 92 bps to 2.0% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 2.0%, 26.58%, and 7.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	30.93%
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	3.37%
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	29.03%
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	-12.95%
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	19.00%
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	-11.11%
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	23.79%
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	21.48%
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-27.93%
10	OptimizeRx	164.25 Mn	140.15 Mn	15.69 Mn	-0.43%

Download Data